Business
Health and Business
The FDA approved a new therapy from Roivant for treating dermatomyositis. This marks an important step in the treatment of rare autoimmune diseases.
Coverage timeline — 2 articles
STAT News
The FDA approved a new medicine from Roivant and its subsidiary Priovant for the treatment of dermatomyositis, a rare autoimmune disease.
2026-08-27 19:47 UTC
CNBC
Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients with Type 2 diabetes.
2026-03-18 19:59 UTC